NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats

Hypertension

Volumn 35, Issue 1 II, 2000, Pages 193-201

  Muller, Dominik N ^a   Dechend, Ralf ^a   Mervaala, Eero M A ^e   Park, Joon Keun ^a   Schmidt, Folke ^a   Fiebeler, Anette ^a   Theuer, Jürgen ^a   Breu, Volker ^c   Ganten, Detlev ^b   Haller, Hermann ^a   Luft, Friedrich C ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d FRANZ VOLHARD CLINIC   (Germany)

^e NONE

Author keywords

Angiotensin II; Cell adhesion molecules; Inflammatory response; Nitric oxide synthase; Proteins; Proto oncogenes

Indexed keywords

ANGIOTENSIN; ANTIOXIDANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PROTEIN C FOS; PROTEIN C JUN; PYRROLIDINE DITHIOCARBAMATE; TRANSCRIPTION FACTOR AP 1; ANGIOTENSIN II; DNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; RENIN; THIOCARBAMIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD VESSEL INJURY; CELL INFILTRATION; CONFERENCE PAPER; CONTROLLED STUDY; DNA BINDING; ELECTROPHORETIC MOBILITY; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY FAILURE; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; TRANSACTIVATION; TRANSGENIC ANIMAL; ANIMAL; ARTICLE; BLOOD PRESSURE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; KIDNEY CIRCULATION; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PROTEIN BINDING; SPRAGUE DAWLEY RAT; VASCULITIS;

ANGIOTENSIN II; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIOXIDANTS; BLOOD PRESSURE; CHEMOKINE CCL2; CORONARY CIRCULATION; CORONARY DISEASE; DNA; GENE EXPRESSION; HUMANS; HYPERTENSION; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY DISEASES; MALE; NF-KAPPA B; NITRIC OXIDE SYNTHASE; PROTEIN BINDING; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; RENIN; RNA, MESSENGER; THIOCARBAMATES; TRANSCRIPTION FACTOR AP-1; VASCULITIS;

EID: 0033630346     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.35.1.193     Document Type: Conference Paper

References (51)

1. Ingelfinger JR, Dzau VJ. Molecular biology of renal injury: emphasis on the role of the renin-angiotensin system. J Am Soc Nephrol. 1991;2: S9-S20.
2. Lindpaintner K, Ganten D. The cardiac renin-angiotensin system: an appraisal of present experimental and clinical evidence. Circ Res. 1991; 68:905-921.
3. Haller H, Park JK, Dragun D, Lippoldt A, Luft FC. Leukocyte infiltration and ICAM-1 expression in two-kidney one-clip hypertension. Nephrol Dial Transplant. 1997;12:899-903.
4. Hsueh WA, Law RE, Do YS. Integrins, adhesion, and cardiac remodeling. Hypertension. 1998;31:176-180.
5. Roy-Chaudhury P, Hillis G, McDonald S, Simpson JG, Power DA. Importance of the tubulointerstitium in human glomerulonephritis, II: distribution of integrin chains beta 1, alpha 1 to 6 and alpha V. Kidney Int. 1997;52:103-110.
6. Ridker PM, Hennekens CH, Roitman Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
7. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448-1456.
8. Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989;58:227-229.
9. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
10. Marumo T, Schini Kerth VB, Brandes RP, Busse R. Glucocorticoids inhibit superoxide anion production and p22 phox mRNA expression in human aortic smooth muscle cells. Hypertension. 1998;32:1083-1088.
11. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 1996;10:709-720.
12. Ozes O, Mayo L, Gustin J, Pfeffer S, Pfeffer L, Donner D. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82-85.
13. Takahashi T, Taniguchi T, Konishi H, Kikkawa U, Ishikawa Y, Yokoyama M. Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol. 1999;276: H1927-H1934.
14. Ushio-Fukai M, Alexander R, Akers M, Yin Q, Fujio Y, Walsh K, Griendling K. Reactive oxygen species mediate the activation of Akt/ protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem. 1999;274:22699-22704.
15. Hernandez-Presa MA, Bustos C, Ortego M, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol. 1998;153:1825-1837.
16. Morrissey JJ, Klahr S. Rapid communication: enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int. 1997;52:926-933.
17. Ruiz-Ortega M, Bustos C, Hernandez-Presa M, Lorenzo O, Plaza J, Edigo J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kB activation and monocyte chemoattractant protein-1 synthesis. J Immunol. 1998;161: 430-439.
18. Liu S, Ye X, Malik A. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation. 1999;100:1330-1337.
19. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med. 1992;175:1181-1194.
20. Nobel CI, Kimland M, Lind B, Orrenius S, Slater AF. Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redoxactive copper. J Biol Chem. 1995;270:26202-26208.
21. Galter D, Mihm S, Droge W. Distinct effects of glutathione disulphide on the nuclear transcription factor kappa B and the activator protein-1. Eur J Biochem. 1994;221:639-648.
22. Abate C, Patel L, Rauscher FJD, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science. 1990;249:1157-1161.
23. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 1993;12:2005-2015.
24. Luft FC, Mervaala EMA, Muller DN, Gross V, Park J-K, Schmitz C, Lippoldt A, Breu V, Dragun D, Dechend R, Schneider W, Ganten D, Haller H. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension. 1999;33:212-218.
25. Mervaala EMA, Muller DN, Park J-K, Schmidt F, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 1999;33:389-395.
26. Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Menard J, Murakami K, Luft FC, Ganten D. High human renin hypertension in transgenic rats. Hypertension. 1997;29:428-434.
27. Altura BM, Gebrewold A. Pyrrolidine dithiocarbamate attenuates alcohol-induced leukocyte-endothelial cell interaction and cerebral vascular damage in rats: possible role of activation of transcription factor NF-kappaB in alcohol brain pathology. Alcohol. 1998;16:25-28.
28. Rangan GK, Wang Y, Tay YC, Harris DC. Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. 1999;56:118-134.
29. Dragun D, Tullius SG, Park JK, Maasch C, Lukitsch I, Lippoldt A, Gross V. Luft FC, Haller H. ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation. Kidney Int. 1998;54:590-602.
30. Mervaala E, Muller D, Schmidt F, Park J-K, Gross V, Bader M, Breu V, Ganten D, Haller H, Luft F. Angiotensin II induces perivascular inflammation and cell proliferation independent of blood pressure in high human renin hypertension. Hypertension. In press.
31. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715-1722.
32. Krappmann D, Wulczyn FG, Scheidereit C. Different mechanisms control signal-induced degradation and basal turnover of the NF-κB inhibitor IκBα in vivo. EMBO J. 1996;15:6716-6726.
33. Zabel U, Henkel T, Silva MS, Baeuerle PA. Nuclear uptake control of NF-kappa B by MAD-3, an IκB protein present in the nucleus. EMBO J. 1993;12:201-211.
34. Muller DN, Fischli W, Clozel JP, Hilgers KF, Bohlender J, Menard J, Busjahn A, Ganten D, Luft FC. Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res. 1998;82:13-20.
35. Rosen P, Du X, Tschope D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by α-tocopherol? Mol Cell Biochem. 1998;188:103-111.
36. Scheidegger KJ, Du J, Delafontaine P. Distinct and common pathways in the regulation of insulin-like growth factor-1 receptor gene expression by angiotensin II and basic fibroblast growth factor. J Biol Chem. 1999;274: 3522-3530.
37. Munoz C, Castellanos MC, Alfranca A, Vara A, Esteban MA, Redondo JM, de Landazuri MO. Transcriptional up-regulation of intracellular adhesion molecule-1 in human endothelial cells by the antioxidant pyrrolidine dithiocarbamate involves the activation of activating protein-1. J Immunol. 1996;157:3587-3597.
38. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation. 1998;98:794-799.
39. Hamaguchi A, Kim S, Izumi Y, Zhan Y, Yamanaka S, Iwao H. Contribution of extracellular signal-regulated kinase to angiotensin II-induced transforming growth factor-b1 expression in vascular smooth muscle cells. Hypertension. 1999;34:126-131.
40. Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M. Reactive oxygen intermediates mediate angiotensin II-induced c-Jun.c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem. 1995;270:22129-22134.
41. Moriguchi Y, Matsubara H, Mori Y, Murasawa S, Masaki H, Maruyama K, Tsutsumi Y, Shibasaki Y, Tanaka Y, Nakajima T, Oda K, Iwasaka T. Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fibronectin and transforming growth factor-β synthesis via transcriptional and posttranscriptional mechanisms. Circ Res. 1999; 84:1073-1084.
42. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med. 1997;3:894-899.
43. Benigni A, Remuzzi G, Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol. 1996;16:151-159.
44. Abbate M, Zoja C, Corna D, Capitanio M, Bertani T, Remuzzi G. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol. 1998;9:1213-1224.
45. Abbate M, Zoja C, Rottoli D, Corna D, Perico N, Bertani T, Remuzzi G. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol. 1999;10: 804-813.
46. Liu SF, Ye X, Malik AB. In vivo inhibition of nuclear factor-kappa B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol. 1997; 159:3976-3983.
47. Spink J, Cohen J, Evans TJ. The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase: activation by nuclear factor-kappa B. J Biol Chem. 1995;270:29541-29547.
48. Perrella MA, Patterson C, Tan L, Yet SF, Hsieh CM, Yoshizumi M, Lee ME. Suppression of interleukin-1beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta1 in vascular smooth muscle cells: evidence for mechanisms other than NF-kappaB. J Biol Chem. 1996;271:13776-13780.
49. Wong HR, Finder JD, Wasserloos K, Lowenstein CJ, Geller DA, Billiar TR, Pitt BR, Davies P. Transcriptional regulation of iNOS by IL-1 beta in cultured rat pulmonary artery smooth muscle cells. Am J Physiol. 1996;271:L166-L171.
50. Hobbs A, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Ann Rev Pharmacol Toxicol. 1999;39: 191-200.
51. Klahr S. The role of L-arginine in hypertension and nephrotoxicity. Curr Opin Nephrol Hypertens. 1998;7:547-550.